Therefore, our data show that upfront tumor genotyping of advanced DTC should always include at least TERT and TP53, to identify those high-risk patients for whom systemic treatment could be considered earlier in case of persistent or recurrent disease. The gene discussed is TP53; the disease is neoplasm.